Business

Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan

Press Release Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan Exclusive Japanese partner Kowa has initiated a Phase 3 safety clinical trial of NCX 470 for the treatment of ocular hypertension in JapanTriggers a €2 million milestone payment to Nicox August 5, 2025 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that its exclusive Japanese partner, Kowa, has initia

Nicox SaAugust 5, 20254
Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan

About this update from Nicox Sa

Attachment

View stock analysis, news, and events for Nicox Sa

Sophia AntipolisNicoxJapanClinical Trialocular hypertensioninternational ophthalmologysafety trialKowa

More from Nicox Sa

All Nicox Sa news →